Which Bisphosphonate? It's the Compliance!: Decision Analysis
Journal of Bone Metabolism
;
: 79-83, 2016.
Article
Dans Anglais
| WPRIM
| ID: wpr-213428
ABSTRACT
BACKGROUND:
The best options of several bisphosphonates for prevention of osteoporotic fractures in postmenopausal women remain controversial. We determined which bisphosphonate provides better efficacy in prevention of osteoporotic fractures using a decision analysis tool, in terms of quality of life.METHODS:
A decision analysis model was constructed containing final outcome score and the probability of vertebral and hip fracture within 1 year. Final outcome was defined as health-related quality of life, and was used as an utility in the decision tree. Probabilities were obtained by literature review, and health-related quality of life was evaluated by consensus committee. A roll back tool was used to determine the best bisphosphonate, and sensitivity analysis was performed to compensate for decision model uncertainty.RESULTS:
The decision model favored bisphosphonate with higher compliance in terms of quality of life. In one-way sensitivity analysis, ibandronate was more beneficial than the others, when probability of compliance on ibandronate was above 0.589.CONCLUSIONS:
In terms of quality of life, the decision analysis model showed that compliance was most important for patients in real world, regardless of type of bisphosphonate.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Qualité de vie
/
Arbres de décision
/
Techniques d'aide à la décision
/
Observance par le patient
/
Compliance
/
Incertitude
/
Consensus
/
Diphosphonates
/
Fractures ostéoporotiques
/
Hanche
Type d'étude:
Guide de pratique
/
Évaluation en économique de la santé
/
Étude pronostique
Limites du sujet:
Femelle
/
Humains
langue:
Anglais
Texte intégral:
Journal of Bone Metabolism
Année:
2016
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS